MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer
Authors
Keywords
-
Journal
Scientific Reports
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-06-25
DOI
10.1038/s41598-021-92552-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1
- (2020) En-Chi Hsu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress
- (2020) Michael D. Nyquist et al. Cell Reports
- ONECUT2 is a driver of neuroendocrine prostate cancer
- (2019) Haiyang Guo et al. Nature Communications
- Dietary Compounds as Epigenetic Modulating Agents in Cancer
- (2019) Ángeles Carlos-Reyes et al. Frontiers in Genetics
- Next-generation characterization of the Cancer Cell Line Encyclopedia
- (2019) Mahmoud Ghandi et al. NATURE
- Genomic correlates of clinical outcome in advanced prostate cancer
- (2019) Wassim Abida et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes
- (2019) Elizabeth J. Adams et al. NATURE
- Clinical features of neuroendocrine prostate cancer
- (2019) Vincenza Conteduca et al. EUROPEAN JOURNAL OF CANCER
- MCM2, MCM4, and MCM6 in Breast Cancer: Clinical Utility in Diagnosis and Prognosis
- (2019) Marianne Samir Makboul Issac et al. NEOPLASIA
- Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer
- (2019) Alexandra N. Corella et al. CLINICAL CANCER RESEARCH
- The epigenetic and transcriptional landscape of neuroendocrine prostate cancer
- (2019) Alastair Davies et al. ENDOCRINE-RELATED CANCER
- Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
- (2018) Rahul Aggarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence
- (2018) Mingyu Liu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis
- (2018) Mirja Rotinen et al. NATURE MEDICINE
- LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics
- (2017) Holly M. Nguyen et al. PROSTATE
- SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 - and RB1 -deficient prostate cancer
- (2017) Ping Mu et al. SCIENCE
- Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance
- (2017) Sheng Yu Ku et al. SCIENCE
- Emerging Variants of Castration-Resistant Prostate Cancer
- (2017) Panagiotis J. Vlachostergios et al. Current Oncology Reports
- Ki67, PCNA, and MCM proteins: Markers of proliferation in the diagnosis of breast cancer
- (2016) Miroslava Juríková et al. ACTA HISTOCHEMICA
- N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer
- (2016) Etienne Dardenne et al. CANCER CELL
- N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells
- (2016) John K. Lee et al. CANCER CELL
- Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer
- (2016) Akash Kumar et al. NATURE MEDICINE
- Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
- (2016) Himisha Beltran et al. NATURE MEDICINE
- The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer
- (2016) Jennifer L. Bishop et al. Cancer Discovery
- Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal TreatmentRelated Neuroendocrine Prostate Cancer
- (2015) Juan Miguel Mosquera et al. NEOPLASIA
- Small cell carcinoma of the prostate
- (2014) Rosa Nadal et al. Nature Reviews Urology
- Ciprofloxacin is an inhibitor of the Mcm2-7 replicative helicase
- (2013) Nicholas Simon et al. BIOSCIENCE REPORTS
- Epigenetic Regulation of Multiple Tumor-Related Genes Leads to Suppression of Breast Tumorigenesis by Dietary Genistein
- (2013) Yuanyuan Li et al. PLoS One
- Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment of NSCLC
- (2012) TOMASZ KLOSKOWSKI et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
- (2011) H. Beltran et al. Cancer Discovery
- Regulation of Minichromosome Maintenance Gene Family by MicroRNA-1296 and Genistein in Prostate Cancer
- (2010) Shahana Majid et al. CANCER RESEARCH
- Minichromosome maintenance (MCM) protein 4 as a marker for proliferation and its clinical and clinicopathological significance in non-small cell lung cancer
- (2010) Junko Kikuchi et al. LUNG CANCER
- Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
- (2009) William P Harris et al. Nature clinical practice. Urology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started